Table 2.
Correlations of PIK3CA H1047R mutation and baseline characteristics in early TNBC (n=90)
| Characteristic | No. | PIK3CA H1047 wildtype | PIK3CA H1047R mutation | Mutation (%) | p-value |
|---|---|---|---|---|---|
| Age (yr) | |||||
| < 50 | 43 | 42 | 1 | 2.3 | 0.113 |
| ≥ 50 | 47 | 41 | 6 | 12.8 | |
| Histology | |||||
| Ductal invasive | 86 | 79 | 7 | 8.1 | > 0.99 |
| Other | 4 | 4 | 0 | 0 | |
| Tumor category | |||||
| cT1-2 | 79 | 73 | 6 | 7.6 | > 0.99 |
| cT3-4 | 11 | 10 | 1 | 9 | |
| LN status | |||||
| Negative | 61 | 56 | 5 | 8.2 | > 0.99 |
| Positive | 26 | 24 | 2 | 7.7 | |
| Missing | 3 | ||||
| Tumor grade | |||||
| 1-2 | 23 | 20 | 3 | 13 | 0.366 |
| 3 | 67 | 63 | 4 | 6 | |
| Treatment | |||||
| PM | 45 | 43 | 2 | 4.4 | 0.434 |
| PMCb | 45 | 40 | 5 | 11.1 | |
| LPBC | |||||
| Yes | 29 | 27 | 2 | 6.9 | > 0.99 |
| No | 61 | 56 | 5 | 8.2 |
Statistical significance was tested by Fisher exact test. TNBC, triple-negative breast cancer; LN, lymph node; PM, paclitaxel plus nonpegylated liposomal doxorubicin; PMCb, PM combined with carboplatin; LPBC, lymphocyte-predominantly breast cancer.